1. Home
  2. WWR vs ACRV Comparison

WWR vs ACRV Comparison

Compare WWR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

BUY

Current Price

$0.41

Market Cap

68.8M

ML Signal

BUY

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
ACRV
Founded
1977
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
74.0M
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
WWR
ACRV
Price
$0.41
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$2.17
★ $11.50
AVG Volume (30 Days)
★ 693.8K
257.4K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 15.13
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$1.27
52 Week High
$1.74
$3.56

Technical Indicators

Market Signals
Indicator
WWR
ACRV
Relative Strength Index (RSI) 24.86 38.70
Support Level $0.38 $1.61
Resistance Level $0.45 $2.21
Average True Range (ATR) 0.03 0.11
MACD -0.01 -0.03
Stochastic Oscillator 1.47 15.47

Price Performance

Historical Comparison
WWR
ACRV

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: